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Abstract
Targeted drugs have significantly improved the therapeutic options for advanced renal cell carcinoma (RCC). However,
resistance often develops, negating the benefit of these agents. In the present study, the molecular mechanisms of acquired
resistance towards the histone deacetylase (HDAC) inhibitor valproic acid (VPA) in a RCC in vivo model were investigated.
NMRI:nu/nu mice were transplanted with Caki-1 RCC cells and then treated with VPA (200 mg/kg/day). Controls remained
untreated. Based on tumor growth dynamics, the mice were divided into ‘‘responders’’ and ‘‘non-responders’’ to VPA.
Histone H3 and H4 acetylation and expression of cell signaling and cell cycle regulating proteins in the RCC mouse tumors
were evaluated by Western blotting. Tumor growth of VPA responders was significantly diminished, whereas that of VPA
non-responders even exceeded control values. Cdk1, 2 and 4 proteins were strongly enhanced in the non-responders.
Importantly, Akt expression and activity were massively up-regulated in the tumors of the VPA non-responders. Chronic
application (12 weeks) of VPA to Caki-1 cells in vitro evoked a distinct elevation of Akt activity and cancer cells no longer
responded with cell growth reduction, compared to the short 2 week treatment. We assume that chronic use of an HDAC-
inhibitor is associated with (re)-activation of Akt, which may be involved in resistance development. Consequently,
combined blockade of both HDAC and Akt may delay or prevent drug resistance in RCC.
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Introduction
Renal cell carcinoma (RCC) is the most common renal tumor
with an incidence of 11.8 per 100,000 in industrialized nations [1].
Although the majority of patients with clinically localized tumors
can effectively be cured, those with metastatic RCC have a bleak
prognosis. During the last decade, intensive efforts have been
undertaken to detect tumor specific molecules, with the hope that
pharmacologic blockade of these proteins may counteract
neoplastic progression. Epigenetic changes have been shown to
be induced by abnormal histone deacetylase (HDAC) activity and
to correlate with tumor development and progression. Immuno-
histologic assessment of 44 RCC cases have provided evidence
that decreased histone acetylation is a common alteration in the
malignant phenotype of this tumor entity [2]. Tissue microarray
analysis carried out on 193 patients with RCC revealed an inverse
correlation between histone acetylation and pT-stage, distant
metastasis, Fuhrman grading and RCC progression [3]. Based on
clinical data, it has been suggested that increasing the amount of
acetylated histones by lowering HDAC might be a therapeutic
option for RCC. In fact, in vitro and in vivo experiments point to
distinct growth and invasion blocking properties of HDAC-
inhibitors in RCC models [4–6]. Unfortunately, the therapeutic
benefit demonstrated in pre-clinical studies has not satisfactorily
been affirmed in clinical trials [7,8] and may be due to the patients
having acquired resistance during long-term drug treatment.
Therefore, tumor growth, histone acetylation status and
expression of cell signaling and cell cycle regulating proteins were
compared in RCC cell bearing mice, some of which respond and
some of which do not respond to chronic treatment with the
HDAC-inhibitor valproic acid (VPA). Evidence is presented that
the tumors in non-responders are characterized by a massive up-
regulation of Akt expression and activity. Additional in vitro
experiments demonstrated that Akt re-activation occurs during
long-term VPA treatment.
Materials and Methods
Ethics statement
All animal experiments were performed according to the
German Animal Protection Law and by approval of the local
responsible authorities (Approval Number: A0452/08; Ethics
Committee of the Landesamt fu ¨r Gesundheit und Soziales, Berlin,
Germany).
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RCC Caki-1 cells were purchased from LGC Promochem
(Wesel, Germany). The cells were grown and subcultured in
RPMI 1640 medium (Seromed, Berlin, Germany) supplemented
with 10% FCS, 100 IU/ml penicillin and 100 mg/ml streptomycin
at 37uC in a humidified, 5% CO2 incubator.
Tumor growth in vivo under chronic VPA application
10
7 Caki-1 cells (100 ml volume) were subcutaneously injected
into male NMRI:nu/nu mice (EPO GmbH, Berlin, Germany).
VPA treatment was initiated when tumors had grown to a
palpable size (5–6 mm diameter). VPA (G. L. Pharma GmbH,
Lannach, Austria) was dissolved in 100% peanut oil and injected
once daily i.p. at a dose of 200 mg/kg/day (n=6) for 63 days. The
control group received solvent (n=6). Tumor size was measured
with calipers. Tumor volume, relative tumor volume (relative to
the first treatment day) and treated/control (T/C) values were
calculated. Body weight and mortality were recorded continuously
to determine tolerability. Animals were sacrificed by CO2
ventilation at the humane endpoint, i.e. as soon as the first animal
displayed a 2 cm3 sized tumor (occurred 63 days after tumor cell
injection) and tissue specimens from the nude mice xenografts
were collected and frozen. The expression of cell cycle regulating
and target proteins was evaluated by Western blot analysis.
VPA application to Caki-1 cells in vitro
Cultured Caki-1 cells were exposed to 1 mM VPA (diluted in
cell culture medium) twice a week. The treatment procedure lasted
for 2 versus 12 weeks, after which the cells were subjected to the
MTT assay for 24 h, 48 h and 72 h, or to the Western blot assay
to detect Akt and pAkt. Control cell cultures were not exposed to
VPA. For the MTT assay, 16104 cells/ml were seeded onto 96-
well tissue culture plates (100 ml/well) in cell culture medium
including VPA (controls received cell culture medium alone). After
24, 48 and 72 h, MTT (0.5 mg/ml) was added for an additional
4 h. Thereafter, cells were lysed in a buffer containing 10% SDS
in 0.01 M HCl. The plates were incubated overnight at 37uC, 5%
CO2. Absorbance at 570 nm was determined for each well using a
microplate ELISA reader. Each experiment was done in triplicate.
After subtracting background absorbance, results were expressed
as mean cell number. Cell number at 24 h was set to 100%.
The 2 week application protocol was carried out to resemble
early effects of drug treatment, i.e. tumor cells still sensitive to
VPA. The 12 week application protocol reflects chronic drug
treatment over a longer period of time, when tumor cells begin to
acquire drug non-responsiveness. Cells treated for 2 weeks are
designated ‘‘Short-term’’, cells treated for 12 weeks are designated
‘‘Long-term’’ in the figures.
Blocking studies
The function blocking monoclonal antibody Akt inhibitor VIII
(Akti-1/2; Chemdea, Ridgewood, NJ, USA), was used to block
Akt1 and Akt2 activity in one set of Caki-1 cells (incubated for 1 h
with 1 mM). These cells were designated Akt
low cells. Another cell
set was incubated with cell culture medium alone and served as the
non-blocked cells, designated Akt
high cells. Both Akt
high and Akt
low
cells were then treated with 1 mM VPA and immediately
subjected to the MTT growth assay. Akt
high and Akt
low control
cells were not exposed to VPA. In an additional experiment, the
Caki-1 cells were cultured in serum-free medium for 24 h. The
serum-free medium was then replaced by medium containing
serum, and tumor cells were activated by 100 ng/ml insulin-like
growth factor I (IGF) for another 24 h. Subsequently, Akt
high and
Akt
low cells were exposed to VPA as described above.
Caki-1 cell growth in vitro (MTT growth assay)
Cell growth of Akt
high versus Akt
low cells was assessed using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) dye reduction assay (Roche Diagnostics, Penzberg,
Germany). The Akt
high and Akt
low Caki-1 cells (50 ml, 1610
5
cells/ml) were seeded onto 96-well tissue culture plates. After 24 h
and 120 h, 10 ml MTT (0.5 mg/ml) was added for an additional
4 h. Thereafter, cells were lysed in a buffer containing 10% SDS
in 0.01 M HCl. The plates were allowed to stand overnight at
37uC, 5% CO2. Absorbance at 550 nm was determined for each
well using a microplate ELISA reader. Each experiment was done
in triplicate. After subtracting background absorbance, results
were expressed as mean cell number. The difference between the
24 h and the 120 h cell number was calculated to obtain the 96 h
cell increase. 96 h control values (Akt
high and Akt
low cells not
treated with VPA) were set at 100%.
Western blot analysis
To explore cell cycle regulating proteins in the mouse tumors,
cell lysates were applied to a 7–15% (depending on protein size)
polyacrylamide gel and electrophoresed (90 min, 100 V). The
protein was then transferred to nitrocellulose membranes (1 h,
100 V). After blocking with non-fat dry milk for 1 h, the
membranes were incubated overnight with monoclonal antibodies
directed against cell cycle proteins: cdk1 (IgG1, clone 1), cdk2
(IgG2a, clone 55), cdk4 (IgG1, clone 97), cyclin A (IgG1, clone 25),
cyclin B (IgG1, clone 18), cyclin D1 (IgG1, clone G124–326),
cyclin E (IgG1, clone HE12), Rb (IgG2a, clone 2), p21 (IgG1,
clone 2G12), p27 (IgG1, clone 57), p53 (IgG2b, clone DO-7; all:
mouse, BD Biosciences, Heidelberg, Germany) and p73 (IgG1,
clone ER-15, Dianova GmbH, Hambourg, Germany).
To explore target specificity of VPA, histone acetylation and
HDAC inhibition were evaluated. The following monoclonal
antibodies were used: Histone H3 (rabbit, clone 3H1), acetyl-
Histone H3 (Lys9, rabbit, polyclonal), Histone H4 (mouse, IgGK,
clone L64C1), acetyl-Histone H4 (Lys8, rabbit, polyclonal, all: Cell
Signaling Technology, Danvers, MA, US), Histone Deacetylase 3
(rabbit, polyclonal) and Histone Deacetylase 4 (rabbit, polyclonal,
both: Biomol International, Lo ¨rrach, Germany).
Relevant signaling proteins involved in proliferation of Caki-1
cells in vitro were also examined. The following antibodies were
used: Akt (IgG1, clone 55), phosphoAkt (pAkt, IgG1, clone
104A282, both: mouse, BD Biosciences, Heidelberg, Germany),
p70S6 Kinase (rabbit, IgG, clone 49D7), phospho p70S6 Kinase
(pp70S6K, rabbit, IgG, clone 108D2), PTEN (rabbit, polyclonal),
phospho PTEN (pPTEN, rabbit, IgG, clone 44A7, all: Cell
Signaling Technology, Danvers, MA, USA).
HRP-conjugated goat-anti-mouse IgG and HRP-conjugated
goat-anti-rabbit IgG (both: Upstate Biotechnology, Lake Placid,
NY, USA) served as the secondary antibody. The membranes
were briefly incubated with ECL detection reagent (ECL
TM,
Amersham/GE Healthcare, Mu ¨nchen, Germany) to visualize the
proteins and then analyzed by the Fusion FX7 system (Peqlab,
Erlangen, Germany). ß-actin (Sigma, Taufenkirchen, Germany)
served as the internal control.
Statistics
All experiments were performed 3–6 times. Statistical signifi-
cance was determined with the Wilcoxon–Mann-Whitney-U-test.
Differences were considered statistically significant at a p-value less
than 0.05.
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Chronic application of VPA induces resistance in vivo
All animals survived. Long-term application of VPA resulted in
significant inhibition of tumor cell growth in 50% of the mice. The
remaining 50% did not respond to VPA at all. The tumor mass in
the non-responsive cohort was even slightly enhanced, compared
to untreated controls (fig. 1). Mice with distinct tumor reduction,
compared to controls, were designated ‘VPA responders’, whereas
mice with no tumor reduction under VPA were defined as ‘VPA
non-responders’.
Cell cycle protein expression in responders versus non-
responders
To gain insight into the molecular mechanism of resistance
development, cell cycle regulating proteins were analyzed.
Expression of cdk1, cdk2 and cdk4 in the VPA responders was
similar to the controls. However, cyclin A was profoundly reduced,
and cyclin B, cyclin D1 and cyclin E were slightly diminished in
the responders group. In contrast, cdk1, cdk2 and cdk4, together
with cyclin A and D1, were strongly up-regulated in the VPA non-
responders. Additionally, cyclin B and E were moderately
elevated, compared to the control animals (fig. 2A).
Figure 1. Effect of VPA on tumor volume in Caki-1 xenografts
in mice. Mice in the treatment arm received 200 mg VPA/kg once
daily. Control mice received solvent (n=6). *indicates significant
difference to the control mice.
doi:10.1371/journal.pone.0053100.g001
Figure 2. Western Blot analysis of cell cycle regulating (fig. 2A) and cell signaling proteins (fig. 2B) in tumor tissue from drug-
sensitive (responders) versus drug-resistant mice (non-responders). Control tissue specimens were taken from untreated animals. Cell
lysates (50 mg) were subjected to SDS-PAGE and blotted on the membrane incubated with the corresponding monoclonal antibodies. b-actin served
as the internal control. The figure shows one representative from three separate experiments.
doi:10.1371/journal.pone.0053100.g002
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HDAC and histone analysis were done after 10 weeks of chronic
VPA exposure. No differences in HDAC expression (both
HDAC3 and HDAC4) were seen in treated versus non-treated
animals. A moderate reduction of total and acetylated histone H3
was evident in responders, whereas the H3 and aH3 level were not
altered in the non-responders, compared to the control (fig. 2B).
The tumor suppressor and Akt-inhibitor PTEN, additionally
evaluated, was down-regulated in VPA non-responders. Most
importantly, a massive up-regulation of Akt (both total and
activated) was evoked in the non-responders. In responders there
was a small increase of pAkt, whereas total Akt was strongly
diminished.
Relevance of Akt in VPA resistance development
Since Akt was profoundly elevated in tumor cells resistant to
VPA treatment, the question arose as to whether differing initial
Akt expression levels might be responsible for VPA non-
responsiveness. In a first series of experiments, Akt was blocked
by a function blocking monoclonal antibody in cultured Caki-1
cells (Akt
low) or left unblocked (Akt
high) and the efficacy of VPA in
suppressing cell growth was evaluated. VPA exposure caused cell
growth to be diminished by 2964% in Akt
high cells and by
2766% in Akt
low cells (fig. 3), showing that the anti-growth
potential of VPA is not dependent on the initial Akt expression
level. The same lack of difference in cell growth in Akt
high and
Akt
low RCC cells was found when, pre-activated with IGF, they
were subjected to the cell growth assay (data not shown).
In a second set of experiments, short-term treatment of cultured
Caki-1 cells with VPA for two weeks resulted in a significant
reduction of cell growth, whereas long-term treatment over 12
weeks was associated with drug insensitivity (fig. 4A) and a
profound increase in Akt expression (fig. 4B).
Discussion
Although HDAC-inhibition has led to a distinct reduction of
cancer growth and invasion in preclinical studies, patient trials
have provided mixed results. Epigenetic therapy, consisting of
adding hydralazine and VPA to one of the current standard
combination chemotherapies for cervical cancer, has demonstrat-
ed a significant advantage in progression-free survival [9]. The
combination of vorinostat and tamoxifen has been encouraging in
reversing hormone resistance in patients with metastatic breast
cancer [10]. No objective response, but prolonged stable disease,
was observed in a study including patients with several advanced
solid tumor malignancies treated with entinostat in combination
with 13-cis retinoic acid [11]. However, additive use of panobino-
stat in patients with solid tumors did not consistently inhibit
HDAC activity [12].
The reason for the clinical insufficiency of HDAC-inhibitors is
not clear to date. Based on an in vivo RCC model, evidence is
presented here showing that chronic VPA application causes
resistance. The in vivo data have been corroborated by in vitro
studies revealing resistance acquisition with long-term VPA
exposure. Therefore, it seems plausible that failure of an
HDAC-inhibitor based regimen might be due to resistance
development.
Molecular analysis has revealed a massive up-regulation of cdk
and cyclin type proteins in drug resistant RCC. Cdk-cyclin
complexes operate as the major cell signaling components in all
stages of the cell cycle. Nevertheless, only limited data are
available dealing with the role of these molecules in RCC.
Immunohistochemical investigation of RCC tissue samples dem-
onstrated cyclin D1 and D3 expression to be closely associated
with tumor size, stage and grade [13,14]. The corresponding
partner, cdk4, was particularly linked to von Hippel-Lindau
negative RCC [15]. A uni- and multivariate statistical analysis
indicated the significant role of cyclin B in RCC development and
pathogenesis [16]. There is also evidence that high cyclin A
expression is an unfavorable prognostic factor in patients with
RCC [13].
Resistance development caused by an HDAC-inhibitor based
regimen is, at least partially, characterized by a distinct
accumulation of cdk/cyclin proteins, which may re-activate the
cell cycle machinery. RCC cells chronically treated with VPA for
12 weeks in vitro have been shown to increase cyclin A and cyclin
D3 expression and to simultaneously regain the capacity to grow
[17]. However, quantitative modification of cdk proteins was not
observed in this model. Possibly, the in vitro conditions differ from
the in vivo one presented here and identical results cannot be
expected. Studies investigating the relevance of cdk-cyclin
complexes in drug resistant RCC cells are necessary.
The VPA-induced resistance could be due to increased levels of
HDAC accompanied by reduced histone acetylation. However,
neither HDAC3/HDAC4, nor H3/H4 acetylation was altered in
the drug resistant mice, compared to the untreated control. This is
important, since the HDAC system would be the specific target of
an HDAC-inhibitor. Obviously, a feedback mechanism in the
course of resistance development has not been established, leading
to an up-regulation of HDAC and down-regulation of histone
acetylation. Recently, resistance to the HDAC-inhibitor SAHA
has been reported not to be accompanied by elevated expression
of HDAC1 and HDAC3 in human colorectal adenocarcinoma
cells [18]. However, this does not mean that HDAC is irrelevant
Figure 3. VPA acts on Caki-1 growth, independent of the initial
Akt expression level. Akt
high and Akt
low expressing Caki-1 cells,
which were generated by a function blocking anti-Akt monoclonal
antibody, were treated with 1 mM VPA (controls remained untreated)
and subjected to the MTT cell growth assay (figure 3A). One
representative from 6 experiments. *indicates significant difference to
controls.
doi:10.1371/journal.pone.0053100.g003
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must also be considered: VPA enhances histone H3 and H4
acetylation in RCC cells at a very early time point. This effect is
lost following long-term exposure. The H3 and H4 acetylation
levels are then similar to the expression level of untreated control
cells [17]. Hypothetically, resistance to VPA might be defined by
the failure to up-regulate histone acetylation (rather than by the
feedback mechanism to diminish histone acetylation).
The most prominent effect of VPA was a massive amplification
of Akt expression and activity in the non-responders as demon-
strated by western blotting, which did not occur in the untreated
mice. Akt plays a central role in the control of cell growth, survival
and angiogenesis, whereby aberrant activation and dysfunction
becomes evident in progressive RCC [19,20]. Due to this
relationship, blocking Akt and Akt downstream molecules by
mammalian target of rapamycin (mTOR) inhibitors has been
considered an effective strategy in fighting this disease. Indeed,
mTOR-suppression has produced robust clinical effects in RCC,
particularly in the early treatment phase. However, compensatory
Akt (re)activation seems to be a critical event under long-term
application, which may limit the antitumor effect of mTOR-
inhibitors [21]. The data presented here demonstrates that up-
regulation of Akt is not a resistance phenomenon exclusively
restricted to the use of mTOR-inhibitors, but may also occur in
the presence of HDAC-inhibitors. This property could label Akt as
a ubiquitous prognostic and therapeutic parameter for patients
subjected to targeted drugs. Recently, resistance of colon cancer
cells to the HDAC-inhibitor butyrate has been demonstrated to be
coupled to high Akt levels [22].
The molecular mechanism responsible for VPA non-respon-
siveness is not yet clear. Based on in vivo results, two hypotheses
are conceivable: 1) RCC cells are initially equipped with a huge
mass of highly activated Akt, which counteracts the antigrowth
potential of VPA exerted by HDAC-inhibition. Since altering the
Akt level in RCC cells in vitro did not influence the efficacy of
VPA to diminish growth, this hypothesis seems unlikely. 2)
Chronic VPA application induces Akt elevation in RCC cells over
time, finally leading to drug non-responsiveness. The in vitro
studies presented here, conducted with therapeutically relevant
VPA concentrations, provide evidence that Akt rises with long-
term VPA treatment of RCC cells, which negatively correlates
with the capacity of VPA to stop cancer growth. In another
experimental setting, prolonged exposure of gastric cancer cells to
increasing concentrations of butyrate resulted in the acquisition of
resistance, which was accompanied by Akt up-regulation [22].
Furthermore, the sensitivity of lung adenocarcinoma cells to the
HDAC-inhibitor FK228 inversely depends on the Akt signaling
pathway [23]. Therefore, the RCC cells may establish undesired
feedback loops in the presence of VPA. Akt may serve as the
dominant counter regulator, finally enabling the cancer cells to
restart their growth program.
Figure 4. Long-term exposure of VPA causes drug resistance and Akt up-regulation. Fig. 4A: Caki-1 cells were treated for 2 weeks (short-
term) or 12 weeks (long-term) with 1 mM VPA, and cell growth was analysed by the MTT assay. Controls remained untreated. The figure shows one
representative from six separate experiments. *indicates significant difference to controls. Fig. 4B: To evaluate Akt expression and activity, Caki-1 cells
were treated short-term or long-term with 1 mM VPA. Controls remained untreated. Cell lysates were subjected to SDS-PAGE and blotted on the
membrane incubated with the respective monoclonal antibodies. b-actin served as the internal control. One representative from three separate
experiments.
doi:10.1371/journal.pone.0053100.g004
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HDAC and Akt may prevent VPA driven resistance induction.
Chronic application of either VPA or the mTOR-inhibitor
everolimus has caused drug non-responsiveness in RCC cells,
which however, could be prevented when both agents were used in
combination [17]. A novel strategy has been provided by Qian
and coworkers to overcome the dynamic and adaptive natures of
tumor cells. They constructed a dual-acting compound by
incorporating HDAC inhibitory functionality into an Akt inhibitor
pharmacophore. Greater growth inhibition and proapoptotic
activity than single-target Akt- or HDAC- inhibitors in both
cultured and implanted cancer cells was shown [24]. Disrupting
cancer networks via simultaneous interference with the Akt
pathway and epigenetic effects on HDAC may, therefore, offer
improved therapeutic benefits in RCC.
This study reveals that chronic HDAC-inhibition resulted in
drug non-responsiveness of RCC cells. Resistance development
was accompanied by elevated Akt expression and activity,
indicating a cross-link between HDAC and the Akt-pathway.
Ongoing in vivo studies are necessary to verify whether a
combined HDAC- and Akt-inhibitor based regimen might
circumvent or delay the onset of acquired resistance.
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